Descartes-11 in Multiple Myeloma

Overview

This Phase I study will test the safety and anti-myeloma activity of ascending doses of Descartes-11 (autologous CD8+ T-cells expressing an anti-BCMA chimeric antigen receptor) in eligible patients with active multiple myeloma.

SparkCures ID 1010
Trial Phase Phase 1
Enrollment 18 Patients
Treatments
Trial Sponsors
  • Cartesian Therapeutics
NCT Identifier

NCT03994705

Am I Eligible?

The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.

The following criteria is provided for health care professionals.

Inclusion Criteria:

  • Active multiple myeloma that is refractory after at least 2 prior lines of therapy;
  • measurable disease;
  • adequate vital organ function; and
  • no active infection.

US Trial Locations

Accepting Patients

The following is a listing of trial locations that are open and accepting patients.

Verified Medical College of Wisconsin Froedtert Hospital

SparkCures Verified Accurate, up-to-date information. Learn more


Rush University Medical Center

Chicago, IL

Center for Cancer and Blood Disorders

Bethesda, MD

Not Currently Accepting Patients

The following is a listing of trial locations that are not currently open and accepting patients.

Memorial Hospital West Memorial Healthcare System

Pembroke Pines, FL

Florida
Memorial Hospital West Memorial Healthcare System

Pembroke Pines, FL

Illinois
Rush University Medical Center

Chicago, IL

Maryland
Center for Cancer and Blood Disorders

Bethesda, MD

Wisconsin
Verified Medical College of Wisconsin Froedtert Hospital

SparkCures Verified Accurate, up-to-date information. Learn more

Resources

There are no resources, links or videos to display for this clinical trial.